Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022

Published on February 24, 2022

This report describes a recommendation for using a 4-month regimen for the treatment of drug-susceptible pulmonary tuberculosis.

Continue reading on website
Other news

A framework for the promotion of ethical benefit sharing in health research

February 22, 2022
This framework, with examples, is intended as a practical tool to assist research stakeholders with identifying opportunities for benefit sharing, and inculcating intentional benefit sharing in their research programmes from inception. BMJ Global Health

EARLY RELEASE: SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households - Four U.S. Jurisdictions, November 2021-February 2022

February 25, 2022
This report describes how Omicron infection resulted in high transmission among household contacts. Prevention strategies are important to reduce transmission in households.